UNITED
      STATES SECURITIES AND EXCHANGE COMMISSION


Washington,
      D.C. 20549








FORM
      10-QSB








QUARTERLY
      REPORT UNDER SECTION 13 OR 15(d)


OF
      THE
      SECURITIES EXCHANGE ACT OF 1934


FOR
      THE
      QUARTERLY PERIOD ENDED MARCH 31, 2007








Commission
      File Number 000-03125





ADUROMED
      INDUSTRIES, INC.


(Exact
      Name of Small Business Issuer in Its Charter)








Delaware      21-0661726


(State
      or
      other Jurisdiction of    (I.R.S.
      Employer


incorporation
      or organization)    Identification
      Number)







3
      Trowbridge Drive


Bethel,
      Connecticut 06801


(Address
      of Principal Executive offices)





(203)
      798-1080


(Issuer’s
      Telephone Number)








Check
      whether the issuer (1) filed all reports required to be filed by
      Section


13
      or
      15(d) of the Exchange Act during the past 12 months (or for such
      shorter


period
      that the registrant was required to file such reports), and (2) has
      been


subject
      to such filing requirements for the past 90 days.


x
      Yes o No





Indicate
      by check mark whether the registrant is a shell company (as defined
      in


Rule
      12b-2 of the Exchange Act). Yes o No x





State
      the
      number of shares outstanding of each of the issuer's classes of
      common


equity
      as
      of the latest practicable date:  20,683,257
      shares common stock (par value $0.0001 per share) outstanding as of May 11,
      2007.










Transitional
      Small Business Disclosure Format (Check one): Yes o No x









TABLE
      OF
      CONTENTS








PART
      I--FINANCIAL INFORMATION




PageItem
                  1: Financial Statements
              F-1
                  - F-10Item
                  2: Management's Discussion and Analysis or Plan of
                  Operation
              3Item
                  3: Controls and Procedures
              6PART
                  II--OTHER INFORMATIONItem
                  1: Legal Proceedings
              6Item
                  2: Unregistered Sales of Equity Securities and Use of
                  Proceeds
              6Item
                  3: Defaults Upon Senior Securities
              6Item
                  4: Submission of Matters to a Vote of Security Holders
              6Item
                  5: Other Information
              6Item
                  6: Exhibits
              7Signatures
              8










**PART
      I--FINANCIAL INFORMATION**





**Item
      1. Financial Statements**














`


INDEX
      TO
      CONSOLIDATED FINANCIAL STATEMENTS








PAGEUNAUDITED
                CONDENSED CONSOLIDATED BALANCE SHEET
            F2UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE QUARTER ENDED
                MARCH 31, 2007 AND 2006
            F3UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
            F4NOTES
                TO CONSOLIDATED FINANCIAL STATEMENTS
            F5




F-1




ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED BALANCE SHEET
 (Unaudited)




March
                  31,ASSETS
              
              2007Current
                  assetsCash
              
              $
              1,008,111Accounts
                  receivable (net of $16,100 allowance)
              
              
              181,095Revenues
                  in excess of billings
              
              
              131,045Inventory
              
              
              934,494Prepaid
                  expenses
              
              
              44,385Total
                  current assets
              
              
              2,299,130Property,
                  plant and equipment, net
              
              
              422,451Long
                  term deposits
              
              
              18,488Total
                  assets
              
              $
              2,740,069LIABILITIES
                  AND STOCKHOLDERS' DEFICITCurrent
                  liabilitiesAccounts
                  payable and accrued liabilities
              
              $
              1,027,129Deferred
                  revenue
              
              
              154,963Dividends
                  payable
              
              
              549,013Accrued
                  liquidated damages
              
              
              602,000Billings
                  in excess of revenue
              
              
              344,757Current
                  portion of notes payable
              
              
              139,228Total
                  current liabilities
              
              
              2,817,090Long
                  term liabilitiesNotes
                  payable, less current portion
              
              
              70,561Notes
                  payable to related parties
              
              
              182,472Total
                  long term liabilities
              
              
              253,033Total
                  liabilities
              
              
              3,070,123Stockholders'
                  deficitPreferred
                  stock: $.0001 par value; 40,000,000 shares authorized; 22,043,862
                  shares
                  issued and outstanding
              
              
              2,204Common
                  stock: $.0001 par value;130,000,000 shares authorized; 20,683,257
                  shares
                  issued and outstanding
              
              
              2,068Additional
                  paid-in capital
              
              
              7,623,326Accumulated
                  deficit
              
              
              (7,957,652
              )Total
                  stockholders' deficit
              
              
              (330,054
              )Total
                  liabilities and stockholders' deficit
              
              $
              2,740,069


F-2




ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)
  For
                  the quarter endedMarch
                  31,2007
              
              2006RevenuesContract
                  revenues earned
              
              $
                  581,591
              
              $
                  242,114Sales
                  and service revenues
              
              
              189,015
              
              
              98,612Total
                  revenues
              
              
              770,606
              
              
              340,726Cost
                  of sales
              
              
              512,953
              
              
              343,061Gross
                  profit
              
              
              257,653
              
              
              (2,335
              )Operating
                  expensesSalaries
                  and wages
              
              
              416,592
              
              
              385,652General
                  and administrative expenses
              
              
              568,878
              
              
              511,447Depreciation
                  expense
              
              
              23,200
              
              
              7,700Total
                  operating expenses
              
              
              1,008,670
              
              
              904,799Loss
                  from operations
              
              
              (751,017
              )
              
              (907,134
              )Other
                  income and expensesInterest
                  income
              
              
              8,869
              
              
              20,062Interest
                  expense
              
              
              (4,530
              )
              
              (31,694
              )Total
                  other income and expenses
              
              
              4,339
              
              
              (11,632
              )Net
                  loss before income taxes
              
              
              (746,678
              )
              
              (918,766
              )Provision
                  for income tax benefit
              
              
              -
              
              
              -Net
                  loss
              
              $
              (746,678
              )
              $
              (918,766
              )Basic
                  and diluted net loss per common share
              
              $
              (0.04
              )
              $
              (0.05
              )Weighted
                  average common shares outstanding
              
              
              20,683,257
              
              
              20,008,718




F-3


ADUROMED
      INDUSTRIES, INC.





CONDENSED
      CONSOLIDATED STATEMENTS OF CASH FLOWS


(Unaudited)




Quarter
                  endedMarch
                  31,2007
              
              2006Cash
                  flows from operating activities:Net
                  loss
              
              $
              (746,678
              )
              $
              (918,766
              )Adjustments
                  to reconcile net loss tonet
                  cash used in operations:Warrants
                  and options issued for services
              
              
              84,000
              
              
              70,056Depreciation
                  expense
              
              
              23,200
              
              
              7,700Changes
                  in operating assets and liabilities:Accounts
                  receivable
              
              
              (5,858
              )
              
              (68,811
              )Loans
                  receivable
              
              
              -
              
              
              (400
              )Revenues
                  in excess of billings
              
              
              27,170
              
              
              (74,049
              )Inventory
              
              
              (294,688
              )
              
              (462,639
              )Prepaid
                  interest
              
              
              7,143
              
              
              (5,470
              )Accounts
                  payable and accrued liabilities
              
              
              (139,074
              )
              
              543,160Deferred
                  revenue
              
              
              86,860
              
              
              21,068Billings
                  in excess of revenue
              
              
              (21,307
              )
              
              -Dividends
                  payable
              
              
              105,000
              
              
              -Net
                  cash used in operating activities
              
              
              (874,232
              )
              
              (888,151
              )Cash
                  flows from investing activities:Purchase
                  of fixed assets
              
              
              (10,430
              )
              
              (62,841
              )Net
                  cash used in investing activities
              
              
              (10,430
              )
              
              (62,841
              )Cash
                  flows from financing activities:Acquisition
                  of shell company
              
              
              -
              
              
              (600,000
              )Repayment
                  of convertible notes
              
              
              -
              
              
              (52,289
              )Interest
                  on notes payable to related parties
              
              
              -
              
              
              (50,000
              )Repayments
                  of notes payable
              
              
              (2,488
              )
              
              -Repayments
                  of notes payable to related parties
              
              
              2,925
              
              
              -Proceeds
                  from issuance of preferred stock
              
              
              -
              
              
              5,010,970Costs
                  of issuance of preferred stock
              
              
              -
              
              
              (498,827
              )Net
                  cash provided by financing activities
              
              
              437
              
              
              3,809,854Increase
                  in cash and cash equivalents
              
              
              (884,225
              )
              
              2,858,862Cash
                  and cash equivalents, beginning of period
              
              
              1,892,336
              
              
              407,058Cash
                  and cash equivalents, end of period
              
              $
              1,008,111
              
              $
              3,265,920Supplemental
                  disclosures of cash flow information:Cash
                  paid for interest
              
              $
              1,016
              
              $
              7,161Supplemental
                  disclosures of noncash investing and financing activities:Conversion
                  of note to stock
              
              $
              -
              
              $
              200,000Accrual
                of preferred stock dividends
              
              $
              105,000
              
              $
              89,232






F-4




ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS




1. BASIS
      OF
      PRESENTATION





The
      condensed consolidated balance sheet of Aduromed Industries Inc., and
      subsidiaries (“Aduromed”, the “Company” ,“AII”) as of March 31, 2007, the
      condensed consolidated statements of operations for the three month period
      ended
      March 31, 2007 and 2006, the condensed consolidated statement of stockholders’
equity for the three month period ended March 31, 2007, and the condensed
      consolidated statements of cash flows for the three month period ended March
      31,
      2007 and 2006 have been prepared by the Company without audit. In the opinion
      of
      management, the information contained herein reflects all adjustments necessary
      to make the presentation of the Company’s condensed financial position, results
      of operations and cash flows not misleading. All such adjustments are of a
      normal recurring nature.





The
      accompanying condensed consolidated financial statements do not contain all
      of
      the information and disclosures required by accounting principles generally
      accepted in the United States of America and should be read in conjunction
      with
      the consolidated financial statements and related notes included in the
      Company’s annual report on Form 10-KSB for the fiscal year ended December 31,
      2006, filed on March 31, 2007.





The
      accompanying consolidated financial statements have been prepared assuming
      that
      the Company will continue as a going concern, which contemplates the realization
      of assets and satisfaction of liabilities and commitments in the normal course
      of business. The Company has incurred substantial recurring losses, which raises
      substantial doubt about its ability to continue as a going concern. The
      consolidated financial statements do not include any adjustments that might
      result from the outcome of this uncertainty.





The
      Company has available cash and cash equivalents of approximately $1,008,000
      at
      March 31, 2007 which it intends to utilize for working capital purposes and
      to
      continue developing its business. To supplement its cash resources, the Company
      has been pursuing a number of alternative financing arrangements with various
      investment entities. We are currently looking to secure additional working
      capital to provide the necessary funds for us to execute our business plan
      through various sources, including bank facilities, bridge loans and equity
      offerings. However, we continue to incur significant operating losses and the
      resultant reduction of our cash position. We cannot assure that we will be
      able
      to obtain additional funding, and the lack thereof would have a material adverse
      impact on our business. Moreover, any equity funding could be substantially
      dilutive to existing stockholders. The aforementioned factors raise substantial
      doubt about our ability to continue as a going concern.




F-5
 
 ADUROMED
          INDUSTRIES INC
 
 NOTES
          TO
          CONSOLIDATED FINANCIAL STATEMENTS


2. BUSINESS
      DESCRIPTION - ORGANIZATION





Effective
      January 30, 2007, the issuer changed its corporate name from General Devices,
      Inc. to Aduromed Industries, Inc.





On
      January 23, 2006, the Company merged (the “Merger”) with Aduromed Corporation, a
      Delaware corporation (“Aduromed”), whereby Aduromed became the wholly-owned
      subsidiary of the Company and the former holders of the equity in Aduromed
      became holders of equity in AII. Aduromed is the Company’s sole operating
      entity. Reference is sometimes made to the “Companies” when describing the
      business and operations of the combined entities. Otherwise the term “Company”
refers only to AII.





The
      Company designs, fabricates and installs systems to treat regulated medical
      waste on site. Its principal products are the Aduromed MedClean Ô series
      systems. AII through its subsidiary, provides MedClean Ô systems
      to hospitals and other medical facilities as efficient, safe, cost-effective
      and
      legally-compliant solutions as alternatives to incineration or off-site hauling
      of untreated medical waste and to other types of alternative treatment
      technologies and methodologies.




F-6




ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS






3. SUMMARY
      OF SIGNIFICANT ACCOUNTING POLICIES





EARNINGS
      (LOSS) PER COMMON SHARE





The
      net
      earnings (loss) per common share are computed by dividing the net loss for
      the
      period by the weighted average number of shares outstanding for the period.
      Outstanding warrants and options for the quarter ending March 31, 2007 and
      2006
      amounting to 40,773,639 and
      40,323,639 respectively were not included in the calculation for net loss per common share
      because it would be antidilutive.





Outstanding
      Preferred A and B class of stock nor the common stock equivalents associated
      with the conversion feature for the year ending March 31, 2007 and 2006
      amounting to 22,043,862 for both periods of both classes of Preferred stock
      were
      not included in the calculation for net loss per common share as it would be
      antidilutive.





The
      numerator and denominator used in the basic and diluted earnings (loss) per
      share of common stock computations are presented in the following
      table:




For
                  the quarter ended March 31,2007
              
              2006NUMERATOR
                  FOR BASIC AND DILUTED EPS (LPS)Net
                  loss per statement of operations
              
              $
              (746,678
              )
              $
              (918,766
              )Dividend
                  payable to preferred stockholders
              
              
              (105,000
              )
              
              (89,232
              )Net
                  loss to common stockholders
              
              $
              (851,678
              )
              $
              (1,007,998
              )DENOMINATOR
                  FOR BASIC AND DILUTED EPS (LPS)Weighted
                  average shares of common stock outstanding
              
              
              20,683,257
              
              
              20,008,718Basic
                  and diluted EPS (LPS)
              
              $
              (0.04
              )
              $
              (0.05
              )





USE
      OF
      ESTIMATES





The
      preparation of the accompanying financial statements, in conformity with
      generally accepted accounting principles, requires management to make estimates
      and assumptions that affect the reported amounts of assets and liabilities,
      and
      disclosure of contingent assets and liabilities at the date of the financial
      statements, and the reported amounts of revenue and expenses during the
      reporting periods. Actual results could differ from those
      estimates.





CASH
      AND
      CASH EQUIVALENTS





The
      Company considers all highly liquid debt instruments purchased with an original
      maturity of three months or less to be cash equivalents.





The
      Company maintains cash deposits with financial institutions, which from time
      to
      time may exceed Federally insured limits. The Company has not experienced any
      losses and believes it is not exposed to any significant credit risk from cash.
      At March 31, 2007, the Company has cash balances on deposit in one account
      with
      a financial institution in excess of the Federally insured limits by a total
      of
      approximately $900,000.




F-7




ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS




CONTROL
      BY PRINCIPAL STOCKHOLDERS





The
      directors, executive officers and their affiliates or related parties, own
      beneficially and in the aggregate, the majority of the voting power of the
      outstanding shares of the common stock of the Company. Accordingly, the
      directors, executive officers and their affiliates, if they voted their shares
      uniformly,


would
      have the ability to control the approval of most corporate actions, including
      increasing the authorized capital stock of the Company and the dissolution,
      merger or sale of the Company's assets.





DEPENDENCE
      ON PRINCIPAL CUSTOMER





One
      principal customer, Aramark, represents a significant portion of our revenues.
      For the quarter ended March 31, 2007, we recognized approximately $169,685
      or
      22% of total revenue in revenue from Aramark. The amount was immaterial in
      the
      same period last year. The loss of our principal customer would have a
      significant adverse impact on our business.





ACCOUNTS
      RECEIVABLE





The
      Company maintains an accounts receivable ledger to track amounts due from
      individual customers. The Company continuously monitors the creditworthiness
      of
      its customers and has established an allowance for amounts that may be
      uncollectible in the future based on current economic conditions, historical
      payments and specific customer related collection issues. The allowance for
      bad
      debts was $16,100 as of March 31, 2007.





PROPERTY,
      PLANT AND EQUIPMENT





The
      Company has property, plant and equipment that consist of automobiles, computers
      and related accessories, and office furniture. The depreciation is calculated
      using the straight line method over the life of the property. All property
      has a
      useful life of 3 to 10 years. The following table summarizes these assets as
      of
      March 31, 2007.




**March
                31,
                2007**Vehicles
              
              
              41,338Office
                  Furniture
              
              
              180,228Computers
                  and Accessories
              
              
              180,233Leasehold
                  Improvements
              
              
              117,997519,796Accumulated
                  Depreciation
              
              
              97,345422,451


INVENTORY





The
      Company maintains an inventory, which consists primarily of component parts,
      spare parts and disposable goods. The inventory, using the average cost method,
      was $934,494 as of March 31, 2007 and is stated at the lower of cost or market.
      The following table summarizes these assets:




**March
              31,
              2007**Component
                & spare parts
            
            $
            841,408Consumables
            
            
            37,168Advance
                payments
            
            
            55,918Total
                Inventory
            
            $
            934,494




F-8




ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS




REVENUE
      RECOGNITION





The
      Company recognizes revenues from fixed-price and modified fixed-price
      construction type contracts on the percentage-of-completion method, measured
      by
      the percentage of cost incurred to date to estimated total cost for each
      contract. That method is used because management considers total cost to be
      the
      best available measure of progress on the contracts. Because of inherent
      uncertainties in estimating costs, it is at least reasonably possible that
      the
      estimates used will change within the near term. The Company typically bills
      25%
      of the contract at signing, 50% upon delivery of components, and the final
      25%
      upon completion of installation and start-up.





Contract
      costs include all direct material and labor costs and those indirect costs
      related to contract performance. Selling, general and administrative costs
      are
      charged to expense as incurred. Provisions for estimated losses on uncompleted
      contracts are made in the period in which such losses are determined. Changes
      in
      job performance, job conditions, and estimated profitability may result in
      revisions to costs and income, which are recognized in the period in which
      the
      revisions are determined. Changes in estimated job profitability resulting
      from
      job performance, job conditions, contract penalty provisions, claims, change
      orders, and settlements, are accounted for as changes in estimates in the
      current period.





The
      Company provides a one year warranty on the systems it installs. The Company
      also obtains a one year warranty on the system components from the component
      manufacturer, thereby mitigating potential warranty costs. Accordingly, the
      Company has accrued no reserve for warranty. After the warranty term expires
      the
      Company offers a maintenance agreement of one or more years to the customer.
      The
      Customer is billed for, and pays for the maintenance agreement in advance.
      Revenues from such maintenance agreements are recognized ratably over the lives
      of the maintenance agreements, with the excess of the amount collected over
      the
      amount recognized as deferred revenue. At March 31, 2007 the Company had
      $154,963 in deferred revenue from maintenance agreements.





Revenues
      from the sale of accessories, repairs and replacement parts are recognized
      when
      the goods are shipped to the customer in accordance with a valid order
      agreement. The order agreement specifies delivery terms and pricing, and is
      considered to reasonably assure collection from the customer.




F-9




ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS





4.  CONTRACTS
      IN PROGRESS





The
      Company entered into construction type contracts to furnish and install its
      systems in hospitals. There were three outstanding contracts at March 31, 2007.
      The following table summarizes these outstanding contracts:











Contract
              
              Revenue
              
              Amounts
              
              Revenues
                  in
              
              Billings
                  in excessAmount
              
              Recognized
              
              Billed
              
              excess
                  of Billings
              
              of
                  RevenuesOutstanding
                  contracts at March 31, 20071,327,930
              
              
              654,191
              
              
              995,948
              
              
              -
              
              
              341,757993,544
              
              
              990,544
              
              
              993,544
              
              
              -
              
              
              3,000586,414
              
              
              275,276
              
              
              195,471
              
              
              79,805
              
              
              -430,790
              
              
              194,837
              
              
              143,597
              
              
              51,240
              
              
              -131,045
              
              
              344,757


5.  COMMON
      STOCK





Effective
      April 16, 2007, the number of authorized Common Stock of the Company, par value
      $0.0001, was increased from 100,000,000 to 130,000,000. A Certificate of
      Amendment to the Company’s Certificate of Incorporation evidencing such increase
      was filed with the Secretary of State of the State Delaware on April 16,
      2007




F-10




**Item
      2. Management's Discussion and Analysis or Plan of
      Operation**





**Forward
      Looking Statements**





The
      Company is including the following cautionary statement in this Interim Report
      on Form 10-QSB for any forward-looking statements made by, or on behalf of,
      the
      Company including its wholly-owned subsidiary Aduromed Corporation.
      Forward-looking statements include statements concerning plans, objectives,
      goals, strategies, future events or performance and underlying assumptions
      and
      other statements which are other than statements of historical facts. Certain
      statements contained herein are forward-looking statements and accordingly
      involve risks and uncertainties which could cause actual results or outcomes
      to
      differ materially from those expressed in the forward-looking statements. Our
      expectations, beliefs and projections are expressed in good faith and are
      believed by us to have a reasonable basis, including without limitation,
      management’s examination of historical operating trends, data contained in our
      records and other data available from third parties, but there can be no
      assurance that management’s expectation, beliefs or projections will result or
      be achieved or accomplished. In addition to other factors and matters discussed
      elsewhere herein, the following are important factors that, in our view, could
      cause actual results to differ materially from those discussed in the
      forward-looking statements: technological advances by our competitors, changes
      in health care reform, including reimbursement programs, changes to regulatory
      requirements relating to environmental approvals for the treatment of infectious
      medical waste, capital needs to fund any delays or extensions of development
      programs, delays in the manufacture of new and existing products by us or third
      party contractors, market acceptance of our products, the loss of any key
      employees, delays in obtaining federal, state or local regulatory clearance
      for
      new installations and operations, changes in governmental regulations,
      availability of capital on terms satisfactory to us and continuing good
      relations with Aramark Corporation. We are also subject to numerous Risk Factors
      relating to manufacturing, regulatory, financial resources and personnel as
      described in this Annual Report on Form 10-KSB. We disclaim any obligation
      to
      update any forward-looking statements to reflect events or circumstances after
      the date hereof.





**Results
      of Operations**





**Quarter
      Ended March** **31,
      2007 Compared to the Quarter Ended March 31, 2006**





*Net
      Revenue*





Total
      revenue for the quarter ended March 31, 2007 more than doubled to $770,606
      compared with $340,726 for the same period in 2006. Of the revenue increase,
      $339,477 was attributable to an increase of revenues derived from sales of
      our
      MedClean system and a $90,400 increase for the sale of consumables, component
      parts and service contracts. Contract backlog as of March 31, 2007 was
      $1,328,707.





Revenues
      from our MedClean product for the current quarter were $581,591 and $242,114
      in
      the same quarter of 2006. The increased revenue was attributable to activities
      on new contracts awarded in the period and the completion of two contracts
      in
      backlog.





Revenues
      derived from the sale of consumables, component parts and service contracts
      increased by $90,403 or 91.7% to $189,015 from $98,612 in 2006. The revenue
      was
      attributable to increased orders for consumable products and service contracts
      from hospitals that have previously purchased our MedClean system compared
      to
      last year.





Orders
      for the MedClean system are contracted by purchase order and are billed in
      3
      increments. Typically, we bill our customers for 25% of the contact value at
      signing, 50% when the equipment is shipped to the customer and 25% upon
      completion of installation and start-up. Consumables and component parts are
      billed when shipped and service contracts are invoiced at the start of the
      service period and revenue is pro-rated over the life of the contract.




3




*Gross
      Profit*




The
      gross
      profit for the first quarter of 2007 was $257,653 (33.4% of total revenue)
      compared with a gross loss of $(2,335) for 2006, an increase of $259,988. Gross
      profit was favorably impacted by an increase in the activity level in addition
      to improved operating and procurement efficiencies initiated in the second
      half
      of 2006.




The
      components of costs of revenues for products include direct materials, shipping
      and rigging costs and contract labor primarily used to install, repair and
      maintain our equipment.




*Operating
      Expenses*




Total
      operating expenses for the first quarter of 2007 was $1,008,670 compared with
      $904,799 for the same period in 2006, an increase of $103,871or 11.5%. The
      increases included salaries and wages for additional personnel of $57,413 who
      were hired in the second and third quarters of 2006, depreciation on increased
      capital spending in the previous year of $15,500, increased office and
      warehousing space leased in May 2006 amounted to $32,581 All other operating
      expenses decreased $1,623 net.




*Interest
      (Income) Expense*




Interest
      income for the quarter was $8,869 compared with $20,062 of interest income
      in
      the same period of 2006 on reduced cash balances available for investment.
      The
      Company invests its excess cash in a money market account. As of March 31,
      2007
      the interest rate was 3.25%.




Interest
      expense for the current quarter was $4,530 compared with $31,694 in the same
      period of 2006. In the first quarter of 2006, we recognized one time non-cash
      financing costs associated with the issuance of common stock and amortization
      expense for warrants issued amounting to $24,531.




*Net
      loss*




Net
      loss
      for the current quarter was $(746,678) compared to a net loss for the same
      period in 2006 of $(918,766).




*Net
      Loss Attributable to Common Stockholders*




Net
      loss
      attributable to common stockholders for this period of 2007 was $(851,678)
      or
      $(0.04) cents per share (basic and diluted), compared to a net loss of
      $(1,007,998) or $(0.05) cents per share (basic and diluted) for the same period
      in 2006.




During
      the quarter, the Company accrued $105,000 in dividends with an interest rate
      of
      6% on $7,000,000, the total value received for both series A and B preferred
      stock.




4




Financial
      Condition





*Liquidity
      and Capital Resources*





The
      Company’s cash on hand and working capital as of March 31, 2007 are as follows:




**March
                31, 2007**Cash
                on hand
            
            $
            1,008,111Working
                Capital
            
            $
            (517,960
            )





To
      date,
      the Company purchased $10,430 in fixed assets. The Company anticipates
      purchasing approximately $100,000 in additional fixed assets in 2007.





Net
      cash
      used in operating activities totaled $874,232 and $888,151 for the quarter
      ended
      March 31, 2007 and 2006, respectively.





Our
      accounts receivable balance may have dramatic swings from one period to
      another depending upon the timing and the amount of milestone billings
      included in the balance at the end of any accounting period. There are
      three milestone billings representing a percentage of the contract value
      for each installment and our payment terms are ``upon receipt''. Receivable
      balances are typically paid within 15 days of the invoice date. Billings
      for maintenance contracts and consumables are due within 45 days and are
      more numerous but much smaller in value than milestone billings. We review
      our outstanding receivable balances on a regular basis to ensure that the
      allowance for bad debt is adequate.   Due to the varying nature in the
      timing and amounts of the receivable balances as noted above, the change in
      the allowance for doubtful account will not necessarily correlate with the
      increase or decrease in the accounts receivable balance.





Our
      inventory balance may have dramatic swings from one period to another
      depending upon the expected installation date of our MedClean systems and our
      accounts payable balances can have similar swings depending on payment
      terms and any volume purchases or discounts we may take advantage of from
      time to time. During the first quarter of 2007, the Company increased its
      inventory on hand by $294,688 to $934,494 in anticipation of new business
      expected in 2007. The accounts payable balance as of March 31, 2007 was
      $1,027,129.





To
      supplement its cash resources, the Company has been pursuing a number of
      alternative financing arrangements with various investment entities. We are
      currently looking to secure additional working capital to provide the necessary
      funds for us to execute our business plan through various sources, including
      bank facilities, bridge loans and equity offerings. However, we continue to
      incur significant operating losses and the resultant reduction of our cash
      position. We cannot assure that we will be able to obtain additional funding,
      and the lack thereof would have a material adverse impact on our business.
      Moreover, any equity funding could be substantially dilutive to existing
      stockholders. The aforementioned factors raise substantial doubt about our
      ability to continue as a going concern.





AII
      has
      an obligation to pay dividends on the value of its preferred stock at a rate
      of
      6%. To date we have accrued $549,013 in dividends payable.





AII
      has
      accrued $602,000 in liquated damages payable to its Preferred stockholders.





The
      Company with the consent of its Preferred stockholders can pay these obligations
      in kind with common stock based upon certain formulas contained in the
      stockholders purchase agreement.




5




**Controls
      and Procedures**





As
      of the
      three month period ended March 31, 2007 covered by this report, the Company
      carried out, under the supervision and with the participation of the Company's
      management, including its Chief Executive Officer and Chief Financial Officer,
      an evaluation of the effectiveness of the design and operation of the Company's
      disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e)
      under the Securities Exchange Act of 1934). Based upon and as of the date of
      that evaluation, the Chief Executive Officer and Chief Financial Officer
      concluded that the design and operation of these disclosure controls and
      procedures are effective.











**PART
      II--OTHER INFORMATION**





**Item
      1: Legal Proceedings** :





The
      Company has no pending legal proceedings. From time to time, it may be involved
      in various claims, lawsuits or disputes with third parties, and actions
      involving allegations of breach of contract incidental to the normal business
      operations of Aduromed’s business.





**Item
      2. Unregistered Sales of Equity Securities and Use of
      Proceeds**





There
      have been no unregistered sales of the Company’s equity securities during the
      quarter ended March 31, 2007.





**Item
      3. Defaults Upon Senior Securities.**





There
      has
      been no default in the payment of principal, interest, sinking or purchase
      fund
      installment, or any other material default not cured with in 30 days, with
      respect to any indebtedness of the Company exceeding 5 percent of its total
      assets.





**Item
      4. Submission of Matters to a Vote of Security Holders.**





On
      January 8, 2007 the Company distributed to its security holders an Information
      Statement on Schedule 14C regarding an amendment to the Company’s Certificate of
      Incorporation to change the name of the Company from General Devices, Inc.
      to
      Aduromed Industries, Inc. Such amendment was approved by written consent of
      a
      majority of the Company’s security holders and became effective on January 29,
      2007.







On
      March
      26, 2007 the Company distributed to its security holders an Information
      Statement on Schedule 14C regarding an amendment to the Company’s Certificate of
      Incorporation to increase the authorized common stock of the Company from
      100,000,000 shares to 130,000,000 shares. Such amendment was approved by written
      consent of a majority of the Company’s security holders and became effective on
      April 16, 2007.





No
      other
      matters have been submitted to security holders of the Company during the period
      covered by this report. ****  ****




**Item
      5: Other Information**





None




6


**I** **tem
      6. Exhibits**







NUMBER
              DESCRIPTION OF
                EXHIBIT




4.1
              Form
                  of Series A Warrant (incorporated by reference to Exhibit 4.1 to
                  Registrant’s Form 10-KSB, filed April 21,
                  2006).


4.2
            Form
                of Series B Warrant (incorporated by reference to Exhibit 4.2 to
                Registrant’s Form 10-KSB, filed April 21,
                2006).


4.3
            Certificate
                of Designations of Series A Preferred Stock (incorporated by reference
                to
                Exhibit 4.4 to Registrant’s Form 10-KSB, filed April 21,
                2006).


4.4
            Certificate
                of Designations of Series B Preferred Stock (incorporated by reference
                to
                Exhibit 4.5 to Registrant’s Form 10-KSB, filed April 21,
                2006).




10.1
            Amendment,
                dated March 28, 2007, to Agreement, dated as of September 1, 2004,
                between
                Registrant's wholly owned subsidiary, Aduromed Corporation, and Aramark
                Management Services Limited Partnership (incorporated by reference
                to
                Exhibit 10.19 to Registrant’s Form 10-KSB, filed March 30, 2007)(portions
                of this exhibit subject to confidential treatment application are
                omitted
                and filed separately with the Securities and Exchange
                Commission).


31.1*
            Certification
                by the Principal Executive Officer of Registrant pursuant to Section
                302
                of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule
                15d-14(a)).


31.2*
            Certification
                by the Principal Financial Officer of Registrant pursuant to Section
                302
                of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule
                15d-14(a)).


32.1*
            Certification
                by the Chief Executive Officer pursuant to 18 U.S.C. 1350 as adoptedpursuant
                to Section 906 of the Sarbanes-Oxley Act of
                2002.


32.2*
            Certification
                by the Chief Financial Officer pursuant to 18 U.S.C. 1350 as adoptedpursuant
                to Section 906 of the Sarbanes-Oxley Act of
                2002.





*
      Filed
      herein.




7





SIGNATURES





In
      accordance with the requirements of the Exchange Act, the registrant caused
      this
      report to be signed on its behalf by the undersigned, thereunto duly
      authorized.





Registrant





ADUROMED
      INDUSTRIES, INC.




Date:
              May 14,
              2007
            
            
            Date:
              May 14,
              2007By: 
              /s/ Damien R. Tanaka
            
            
            By: 
              /s/ Kevin T. DunphyDamien
                R. Tanaka,
              Chairman of the Board, President
              and Chief Executive Officer
              (Principal Executive Officer)
            
            
            Kevin
                T. Dunphy
              Treasurer and
              Chief Financial Officer
              (Principal Financial and Accounting
                Officer)




8